An interventional study of Red Blood Cell Transfusion and Red Blood Cell Transfusion in Blood Loss Anemia, Extracorporeal Membrane Oxygenation Complication and Disability Physical, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Australian and New Zealand Intensive Care Research Centre · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Hemorrhage with a site in Australia — 7 open to participants now, 11 under way, 7 of them phase 3. Hemorrhage · Australia.
Among the 30 studies in Hemorrhage with a site in Australia, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2023, is one of 4 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 25th registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →7 of the 30 studies in Hemorrhage with a site in Australia are open now. Recruiting first, the newest first:
Takeda · Sites in Australia, United States, Bulgaria and 12 more countries
Ages 18+
Takeda · Sites in Australia, United States, Bulgaria and 15 more countries
Ages 18+
Pfizer · Sites in Australia, United States, Brazil and 11 more countries
Ages 18+ · Men only
Pfizer · Sites in Australia, United States, Argentina and 19 more countries
Ages 1–17 · Men only
Population Health Research Institute · Sites in Australia, Canada, Germany
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 212 across the 26 interventional studies, 9,838 across the 4 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 30 have an industry lead sponsor. The 10 most frequent:
Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.
Australian and New Zealand Intensive Care Research Centre has 2 studies filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Hemorrhage with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04284839Phase 3Population Health Research InstituteThe Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Hemorrhage with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe cases of COVID-19). ECMO acts as a mechanical circulatory support temporarily replacing the function of the heart or lungs by oxygenating blood and removing carbon dioxide, allowing time for these organs to recover. Many critically ill patients, including those on ECMO, have an increased risk of bleeding and reduced production/increased destruction of red blood cells (RBCs). This can lead to anaemia (haemoglobin levels \<120 g/l), a condition where the body lacks enough healthy RBCs to carry enough oxygen to the body's tissues. Therefore, patients on ECMO frequently require RBC transfusion, with clinicians having to decide if administering an RBC transfusion (with its associated risks) is higher than tolerating complications of anaemia.
ROSETTA is a feasibility study that aims to determine the safety and feasibility of randomizing patients on ECMO to a restrictive RBC transfusion strategy (maintain Hb concentration above 70g/L) or to a more liberal transfusion strategy (maintain Hb concentration above 90g/L). Feasibility is defined as the ability to achieve a mean separation of at least 10g/L between the average lowest daily haemoglobin values in the two study groups.
A recent Cochrane analysis recommended a transfusion strategy that minimises the use of RBC transfusions in critically ill patients (by tolerating anaemia to avoid the adverse effects of an RBC transfusion). However, the analysis acknowledges that the degree of anaemia which can be tolerated by such patients is unknown, especially in patients suffering from conditions that limit oxygen delivery to the organs (like cardiac disease). As a result, the Australian Blood Authority's guidelines recommend an RBC transfusion to a patient at an Hb concentration of less than 70 g/L, while a transfusion at a Hb between 70 and 90 g/L should be based on the need to relieve clinical signs and symptoms of anaemia. However, this range is broad, and many studies in the general critically ill cohort have shown lower transfusion triggers are non-inferior to higher transfusion triggers.
No studies have been completed directly evaluating transfusion triggers in the ECMO patient cohort. ECMO patients differ to the general critically ill cohort as they have different physiological requirements, are at higher-risk for poor outcomes, and have an increased requirement for transfusions. Hb is a key driver of oxygen delivery (DO2), and critically ill ECMO patients are more commonly exposed to low DO2 due to low cardiac output and borderline oxygenation. Therefore, studies must be done to evaluate the optimal transfusion trigger/s (as determined by Hb concentration) that optimise mortality and long-term outcomes of ECMO patients.
Should the ROSSETTA Pilot results indicate adequate separation of at least 10g/L between the two study groups, and that patient safety has not been adversely affected by the trial methods, feasibility will be deemed confirmed and the protocol not in need of modification prior to full trial commencement. At this point the ROSETTA Pilot will be transitioned into the Red Blood Cell Transfusion Domain, within RECOMMEND Platform Trial. The Primary and Secondary outcomes of the trial at large, will be answered during this stage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L.
Other: Red Blood Cell Transfusion
if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused. Additional units can be prescribed to raise the Hb concentration to greater than 90g/L
Other: Red Blood Cell Transfusion
Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
Difference in average lowest daily Hb concentration
Primary Outcome Measure
Time frame: From date of randomization to the end of the intervention (assessed up to day 28)
Enrolment Rate
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Reasons for not entering eligible patients into the study
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Mean pre-transfusion Hb concentration immediately prior to an RBC transfusion
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Proportion of RBC transfusions given according to allocated trigger
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Time from measured Hb trigger value to transfusion
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Number of RBC transfusions given prior to randomization
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Frequency for not transfusing a patient who has reached a transfusion trigger
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Reason/s for not transfusing a patient who has reached a transfusion trigger
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Number of protocol deviations
Feasibility Outcome
Time frame: through study completion, an average of 2 years
Number and nature of Serious Adverse Events (SAEs)
Safety and effectiveness outcome
Time frame: through study completion, an average of 2 years
Total blood products used
Safety and effectiveness outcome
Time frame: through study completion, an average of 2 years
Major bleeding events (defined by ISTH criteria)
Safety and effectiveness outcome
Time frame: through study completion, an average of 2 years
Clinically relevant non-major bleeding events: GI haemorrhage, peripheral cannulation site bleeding, mediastinal cannulation site bleeding, surgical site bleeding
Safety and effectiveness outcome
Time frame: through study completion, an average of 2 years
Venous and arterial thromboembolic events
Safety and effectiveness outcome
Time frame: through study completion, an average of 2 years
New onset renal replacement therapy (RRT) during ECMO
Safety and effectiveness outcome
Time frame: through study completion, an average of 2 years
ECMO free days at day 60
Safety and effectiveness outcome
Time frame: 60 days
ICU free days at day 60
Safety and effectiveness outcome
Time frame: 60 days
Patient Reported Outcome Measure - WHODAS 2.0
Disability Safety and effectiveness outcome
Time frame: 6 months
Patient Reported Outcome Measure - IADL
Independent Activities of Daily Living Safety and effectiveness outcome
Time frame: 6 months
Patient Reported Outcome Measure - ADL
Activity of Daily Living Safety and effectiveness outcome
Time frame: 6 months
Patient Reported Outcome Measure - MoCA BLIND
Cognitive Function Safety and effectiveness outcome
Time frame: 6 months
Patient Reported Outcome Measure - EQ-5D-5L
Quality of Life Safety and effectiveness outcome
Time frame: 6 months
Patient Reported Outcome Measure - mRS
Degree of Disability Safety and effectiveness outcome
Time frame: 6 months
Plan to share: No — Patient data is de-identified and only aggregate summaries published.
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Jan 2025, 16 months.
Of 192 non-industry interventional studies with no phase under Hemorrhage, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 16 months is below that.
Counting every sponsor, half of 227 studies reached it within 19 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian and New Zealand Intensive Care Research Centre